Form 4: Spero Therapeutics Director Sells Shares for Tax Obligations

Spero Therapeutics Director Ankit Mahadevia sold 6,572 shares of common stock at $1.97 per share to cover tax withholding obligations related to RSU vesting.

Summary

• Director Ankit Mahadevia of Spero Therapeutics, Inc. sold 6,572 shares of common stock.
• The sale occurred on August 28, 2025, at a price of $1.97 per share.
• The transaction was a 'sell to cover' to satisfy tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) that were granted on August 26, 2021.
• Following this transaction, Mahadevia beneficially owns 703,294 shares of Spero Therapeutics common stock.
• The beneficial ownership includes 65,817 shares held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.
• The transaction was executed under a Rule 10b5-1(c) plan.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine 'sell to cover' for tax obligations upon RSU vesting, which is a common and expected event for executives and not indicative of a change in sentiment towards the company's prospects.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged, non-discretionary sale.
• The sale is specifically for tax withholding purposes, not a discretionary sale of shares by the director.

Negatives

• A director selling shares, even for tax purposes, can sometimes be perceived negatively by some market participants.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it primarily reports an insider transaction.

Industry Context

This filing reports a routine insider transaction and does not provide broader industry context or trends. It is a compliance disclosure for a director's equity activity.

Related Party Transactions

• Beneficial ownership includes 65,817 shares of common stock held by the Mahadevia-Mehta Family Trust, of which the Reporting Person is a trustee.

Stakeholder Impact

• Shareholders: The transaction represents a minor dilution of outstanding shares, but its 'sell to cover' nature typically mitigates negative interpretations regarding insider confidence.

Key Dates

Recommendation

The filing details a routine 'sell to cover' transaction by a director to satisfy tax obligations upon RSU vesting. This is a common and expected event for executives and does not reflect a discretionary sale or a change in the director's long-term view of the company. Therefore, it provides no new fundamental information to warrant a change from a 'hold' recommendation based solely on this filing.

Keywords

Spero Therapeutics, SPRO, Ankit Mahadevia, Insider Transaction, Form 4, Stock Sale, RSU Vesting, Director, Biotechnology